NeutriSci International Inc
VANCOUVER, BC / ACCESSWIRE / August 12, 2021 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSX-V:NU)(OTCQB:NRXCF)(FRANKFURT:1N9), an innovative technology company developing products, licencing IP and technology for B2B partnerships and the nutraceutical industry, is pleased to provide an update on previously announced projects.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Biople: After receiving an exclusive first-to-market period from Tabletz LLC, Biople's sales of Tabletz ranked #2 in product sales in Biople stores and online. Product sales continue to grow along with expanded consumer awareness. Lemon and Berry are the 2 most favored flavors. Consumers are telling Biople that the effectiveness along with the flavors are among the best they have tried. They are pleased that they have a choice over the taste of CBD oil.
Biople represents the #1 retailer of high-end, quality CBD and CBD related products in Japan. Biople, by CosmeKitchen (biople.jp) has 22 locations in Kanto, Tokai, Kinki, Chugoku/Shikoku, Kyushu-Okinawa.
Tabletz LLC.: Tabletz LLC., is expected to receive a sales update in the coming 2 weeks from its distributor in Japan. Information is expected to include product turns, forecasted sales numbers along with other details relating to sales and consumer feedback.
NeutriSci looks forward to presenting the information once it is received. The Company also intends to have a question-and-answer webinar during the week of Aug 23rd. Details of the webinar will be announced once scheduling can be accommodated and after the sales information is received from Tabletz LLC.
About NeutriSci International Inc.
NeutriSci specializes in the innovation, production, and formulation of nutraceutical products. Established in 2009, NeutriSci's is building sustainable sales models with Convenience, Chain Drug, and Mass Market and Supermarket retailers for its products offering co-branding as well as private label opportunities and contract manufacturing services. For more information, please visit: www.neutrisci.com.
On Behalf of the Board of Directors of
NEUTRISCI INTERNATIONAL INC.
Glen Rehman
CEO
Tel: (403) 264-6320
For investor inquiries, please contactinvestors@neutrisci.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.
This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
Statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure, or prevent any disease.
SOURCE: NeutriSci International Inc
View source version on accesswire.com:
https://www.accesswire.com/659446/Neutrisci-Provides-Update-on-Tabletz-Developments
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Investment Firm Alpha Star invests 1 million USD in AI Art Authentication Company Art Recognition29.10.2025 11:00:00 CET | Press release
ZURICH, SWITZERLAND / ACCESS Newswire / October 29, 2025 / Art Recognition , the Swiss pioneer in AI art authentication, is delighted to announce a new strategic partnership with Alpha Star , a leading Luxembourg-based investment fund with a strong track record of supporting innovative companies in the art market. This collaboration marks an important milestone as Alpha Star becomes Art Recognition's anchor investor. The partnership will accelerate Art Recognition's growth and strengthen its position as a trusted technology partner for the art world, helping bring greater transparency, confidence, and innovation to art authentication. "We are thrilled to welcome Alpha Star as a key partner on our journey," said Carina Popovici, CEO and Founder of Art Recognition. "Their confidence in our technology and vision is a strong endorsement of the role AI will play in shaping the future of the art world." "We are excited to support Art Recognition in its mission to bring cutting-edge AI techno
Ecological Threat Report 2025: Extreme Wet-Dry Seasons Emerge as Critical Conflict Catalyst29.10.2025 06:00:00 CET | Press release
Approximately 2 billion people - one quarter of humanity - now live in regions experiencing moderate to severe increases in seasonality LONDON, GB / ACCESS Newswire / October 29, 2025 / New research from the Institute for Economics & Peace reveals that changing rainfall patterns are significantly amplifying conflict risks worldwide. The 2025 Ecological Threat Report (ETR), released today, finds conflict death rates are substantially higher in areas where rainfall is concentrating into fewer months, compared to regions where rain is spreading more evenly throughout the year.Ecological Threat Report 2025 Analysing Ecological Threats, Resilience & Peace Key Findings On average in areas where wet and dry seasons are becoming more extreme, there are four times as many conflict deaths as areas where it has decreased. In 2024, natural hazards triggered 45 million short-term internal displacements across 163 countries, the highest figure since at least 2008. Western Brazil, including parts of
Karbon-X Celebrates Major Milestone in Senegal Mangrove Restoration Project28.10.2025 13:00:00 CET | Press release
Planting completed across 7,000 hectares in partnership with Woodside Energy, advancing community-led climate action. DAKAR, SN / ACCESS Newswire / October 28, 2025 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company") is proud to announce a significant milestone in its ABC Mangrove Project, one of West Africa's largest community-led restoration initiatives with the successful completion of planting across more than 7,000 hectares of mangroves along Senegal's coastline. Developed through ALLCOT, Karbon-X's project development and advisory arm (ALLCOT-A Karbon-X Company), and in partnership with Woodside Energy, the project is helping restore critical blue-carbon ecosystems that protect biodiversity, strengthen local economies, and capture carbon naturally from the atmosphere. Through this multi-year effort, thousands of local community members have been engaged in the planting and care of mangroves, creating new jobs, skills training, and sustainable income opportunities for wome
Florence Healthcare Launches SiteLink on AWS Marketplace, Extending its Clinical Trial Operations Platform Capabilities to Cloud28.10.2025 13:00:00 CET | Press release
ATLANTA, GEORGIA / ACCESS Newswire / October 28, 2025 / Florence Healthcare, the leading clinical trial platform connecting pharmaceutical sponsors and research sites worldwide, announced today that SiteLink, a key offering of Florence's Trial Operations Platform, is now available in AWS Marketplace. SiteLink accelerates study startup and enables real-time document distribution, monitoring, and data exchange with study sites, addressing the critical digital divide in clinical trials. With only 30% of global research sites currently using digital workflows, SiteLink helps bridge this gap by automating sponsor-site operational workflows. Bringing the Florence Trial Operations Platform Benefits to AWS As a core component of Florence's Trial Operations Platform, SiteLink delivers the same proven results that have made Florence the #1 clinical trial management solution for six consecutive years. The platform enables: Faster Startup: Up to 70% faster study activation timelines through automa
GoodData Brings AI-Native Data Intelligence to Financial Services28.10.2025 10:00:00 CET | Press release
Embeddable, compliant, and auditable AI agents unlock trusted automation for banks, insurers, and financial institutions. SAN FRANCISCO, CA / ACCESS Newswire / October 28, 2025 / GoodData, a leading analytics and data intelligence company, today unveiled new finance-focused applications for its composable AI platform, designed to tackle the industry's toughest challenges. By combining its AI Lake, AI Hub, and AI Apps into a single foundation for enterprise data intelligence, the next-generation platform gives financial institutions powerful tools to build and deploy AI agents. These agents can detect and investigate fraud in seconds with audit trails regulators can trust, keeping portfolios compliant in real time within industry guidelines. This streamlines regulatory reporting by compiling, checking, and submitting disclosures transparently, all while meeting strict standards for financial compliance, governance, and security. Purpose-built for finance The financial services sector fa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom